**Core Concept**
The LUMINATE programme refers to a series of clinical trials evaluating the efficacy and safety of a novel drug for treating non-infectious uveitis, a condition characterized by inflammation of the uvea in the eye. This condition often results in vision impairment and requires prompt treatment to prevent long-term damage.

**Why the Correct Answer is Right**
The correct answer is related to a monoclonal antibody that targets a specific protein involved in the inflammatory pathway. Uveitis is often associated with excessive production of pro-inflammatory cytokines, which lead to tissue damage. The drug in question works by binding to and inhibiting the action of a key cytokine, thereby reducing inflammation and preventing tissue damage.

**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because it does not target the specific inflammatory pathway involved in non-infectious uveitis.
**Option B:** This option is incorrect because it is not a drug that has been approved for the treatment of uveitis.
**Option C:** This option is incorrect because it is not a monoclonal antibody and does not work through the same mechanism as the correct answer.

**Clinical Pearl / High-Yield Fact**
The LUMINATE programme highlights the importance of targeting specific molecular pathways in the treatment of non-infectious uveitis, rather than relying on broad-spectrum anti-inflammatory agents that may have more side effects.

**Correct Answer:** . Eculizumab